LCOV
ALXN

London Company of Virginia’s Alexion Pharmaceuticals ALXN Stock Holding History

London Company of Virginia’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-558,734
Closed -$69.4M – 140
2018
Q2 		$69.4M Sell
558,734
-33,099
-6% -$3.87M 0.57% 51
2018
Q1 		$66M Buy
591,833
+5,630
+1% +$673K 0.53% 56
2017
Q4 		$70.1M Sell
586,203
-17,077
-3% -$2.08M 0.51% 57
2017
Q3 		$84.6M Sell
603,280
-17,554
-3% -$2.38M 0.61% 51
2017
Q2 		$75.5M Buy
+620,834
New +$72.3M 0.51% 64

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

London Company of Virginia's ALXN Position: Q3 2018 in Review

London Company of Virginia sold out of Alexion Pharmaceuticals (ALXN) in Q3 2018, closing a stake of 558,734 shares — an estimated $69.4M sold.

London Company of Virginia first reported a position in ALXN in Q2 2017 and held it in 5 quarters. The position peaked at $84.6M in Q3 2017. 585 funds tracked by Wall St. Rank hold ALXN as of Q3 2018.

  • London Company of Virginia reported no remaining Alexion Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • London Company of Virginia sold 558,734 Alexion Pharmaceuticals shares in Q3 2018, an estimated $69.4M.
  • London Company of Virginia first reported a position in Alexion Pharmaceuticals in Q2 2017 and held it in 5 quarters.
  • London Company of Virginia's Alexion Pharmaceuticals position peaked at $84.6M in Q3 2017.
  • 585 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2018.

Based on London Company of Virginia's 13F filing for Q3 2018, filed 14 Nov 2018.